Background: In 2019, the breakthrough of the coronavirus 2 disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represented one of the major issues of our recent history. Different drugs have been tested to rapidly find effective anti-viral treatments and, among these, antiandrogens have been suggested to play a role in mediating SARS-CoV-2 infection. Considering the high heterogeneity of studies on this topic, we decided to review the current literature. Methods: We performed a systematic review according to PRISMA guidelines. A search strategy was conducted on PUBMED and Medline. Only original articles published from March 2020 to 31 August 2023 investigating the possible protective role of antiandrogens were included. In vitro or preclinical studies and reports not in the English language were excluded. The main objective was to investigate how antiandrogens may interfere with COVID-19 outcomes. Results: Among 1755 records, we selected 31 studies, the majority of which consisted of retrospective clinical data collections and of randomized clinical trials during the first and second wave of the COVID-19 pandemic. Conclusions: In conclusion, we can state that antiandrogens do not seem to protect individuals from SARS-CoV-2 infection and COVID-19 severity and, thus, their use should not be encouraged in this field.
背景：2019年，由严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）引发的冠状病毒2型疾病（COVID-19）大流行，成为我们近代史上的重大事件之一。为迅速寻找有效的抗病毒治疗方案，多种药物被投入测试，其中抗雄激素药物被认为可能影响SARS-CoV-2感染进程。鉴于该领域研究存在高度异质性，我们决定对现有文献进行系统性梳理。 方法：本研究遵循PRISMA指南开展系统性综述。通过PUBMED和Medline数据库进行检索，仅纳入2020年3月至2023年8月31日期间发表的、探讨抗雄激素潜在保护作用的原创研究。排除体外研究、临床前研究及非英文文献。主要研究目标是探究抗雄激素如何影响COVID-19的临床结局。 结果：从1755条文献记录中筛选出31项研究，其中大部分为回顾性临床数据收集研究，以及在第一波和第二波COVID-19大流行期间开展的随机临床试验。 结论：综合分析表明，抗雄激素药物似乎不能有效预防SARS-CoV-2感染或降低COVID-19严重程度，因此不应鼓励在该临床领域使用此类药物。
Antiandrogens as Therapies for COVID-19: A Systematic Review
肿瘤(癌症)患者之家